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Synthesis of an orthogonally protected polyhydroxylated 
cyclopentene from L-sorbose 
Daniele Lo Rea*, Leigh Jonesa, Ernest Giraltb,c and Paul Murphya* 
Dedicated to Ma Teresa Plaza  López-Espinosa on the occasion of her retirement ((optional)) 
Abstract: The use of L-sorbose in synthesis of functionalized 
cyclopentene derivatives was accomplished.  These cyclopentene 
derivatives are related to those found in naturally occurring jatrophone 
frameworks and in other bioactive compounds.  The formation of allyl 
α-L-sorbopyranoside was a key synthetic step.  Regioselective 
introduction of protecting groups was followed by the hydrolysis of the 
allyl glycoside to furnish a fully protected acyclic L-sorbose derivative.  
This acyclic intermediate was subsequently used to give an 
orthogonally protected polyhydroxylated cyclopentene, which has 
potential in further bioactive compound synthesis.  The protected 
cyclopentene itself showed a clear cytotoxic activity when tested 
against a panel of human cancer cell lines (HT29, LS174T, SW620, 
A549, HeLa cells). 
The occurrence of resistance to anticancer agents is a major 
obstacle for successful cancer chemotherapy. The emergence of 
resistance to anticancer drugs, in particular multidrug resistance 
(MDR) has made many of the available anticancer drugs 
ineffective.[1] A glycoprotein, ABCB1, also known as P-
glycoprotein, is a membrane protein member of the ABC 
transporters superfamily. These membrane-embedded transport 
proteins decrease the intracellular drug accumulation, by and 
ATP-dependent efflux. This reduces the cytotoxicity of the 
anticancer agent and enables the tumor cells to survive. 
Jatrophanes, such as 1-3, are natural compounds extracted from 
plants of the genus of Euphorbia. A broad range of biological 
properties have been reported for constituents of the plant 
extract.[2] In particular, jatrophanes are potent and specific P-
glycoprotein modulators.[3]  In addition, a variety of other biological 
activities have been reported: inhibitory activity on the mammalian 
mitochondrial respiratory chain,[4] antiviral activity,[5] microtubole 
interaction,[6] antiplasmodial activity,[7] cytotoxicity against various 
human cancer cell lines[8].  
It has been reported that modifications of the cyclopentene (ring 
A) of  the jatrophane framework, resulted  in increased biological 
activity (figure 1).[9] For instance, Hierseman and co-workers[9] 
demonstrated that introduction of aromatic lipophilic substituent at 
C-3 enhanced the ABCB1 inhibitory activity (figure 1). They also 
show that there is a correlation between overall lipophilicity and 
ABCB1 inhibition.[9] 
  
Figure 1. a) Structure of selected jatrophane natural products; b) synthetic 
jatrophane analogues and their activity against ABCB1; c) orthogonally 
protected pyranose 18 and open-chain sorbose derivatives 20 and the 
orthogonal protected cyclopentene 7 prepared herein. 
Nevertheless, the potential to prepare cyclopentene derivatives 
related to those found in 4 and which would ultimately be used to 
give new jatrophone analogues has formed the motivation for the 
work described herein.  We envisaged that the preparation of 
orthogonally protected polyhydroxylated cyclopentanol 7, similar 
to the ring A of the jatrophane framework, is relevant to the 
preparation of jatrophane analogues with increased biological 
activity and for structure-activity relationships.  In addition, 
advanced intermediate 7 can be also used for the preparation of 
biologically active cyclopentitols or cyclopentenols.  These are 
polyhydroxylated cyclopentanes,[10] that display a plethora of 
biological activity such as found for the glycosidase inhibitors 
trehazolin and mannostatin,[10a] [11] the anticancer and antibiotic 
pactamycin,[12] and the insecticide ryanodine.[13] In addition, 
cyclopentenols, are also important because of their presence in 
numerous biologically active targets such as the antibiotic 
pentenomycin,[14] the anti-inflammatory monotropein,[15] and the 
anticancer compound (-)-neplanocin A.[16]  
It was envisaged that the construction of the polyhydroxylated 
cyclopentene could be achieved through a ring-closing 
metathesis[10c, 17] (RCM) reaction of fully protected diene such as 
that in 11. Since RCM could be challenging in such a densely 
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substituted diene,[18] we first prepared 11 in order to validate the 
synthetic strategy.   
  
Scheme 1. Preliminary validation of the synthetic strategy from L-sorbose: 
synthesis of per-O-benzylated cyclopentane 12.  
Compound 9 has been prepared from L-sorbose previously.[19] 
However, in our hands, attempts to simultaneously install olefin at 
C6 and C2 through directly oxidation of 9 followed by a 
concomitant double Wittig reaction were unsuccessful. Oxidation 
of the latent alcohol of 9 under Swern conditions followed by Wittig 
reaction only gave a complex mixture while treatment of 9 with the 
Dess-Martin reagent gave no reaction.  For these reasons, 
aldehyde 10 was first prepared as reported[19] and then treated 
with Ph3PCH3Br and tBuOK to give the desired diene 11. The 
RCM of 11 using the Grubbs 2nd generation catalyst at room 
temperature only gave only recovered starting material. However, 
when the RCM was carried out by heating in refluxing toluene, the 
polyhydroxylated cyclopentene 12 was isolated in good yield 
(76%, Scheme 1). 
With these encouraging observations in hand, it was next decided 
to exploit this strategy for the preparation of an orthogonally 
protected L-sorbose derivative.  Chemical manipulation of L-
sorbose is often carried out via its methyl L-sorbopyranoside[19] or 
its 2,3:4:6-di-O-isopropyliden-α-L-sorbofuranose.[18, 20] However, 
these synthetic approaches suffer drawbacks. In fact, hydrolysis 
of the dioxolane ring (for the L-sorbofuranose) or hydrolysis of the 
methyl glycoside (for the L-sorbopyranoside) requires strong 
acidic conditions, which are not compatible with several functional 
or protecting groups. On other hand, the allyl group[21] can be 
removed in the presence of different protecting groups[22] under 
relatively mild conditions.[23] Since the synthesis of the L-
sorbopyranoside 8 is achieved using MeOH in the presence of 
acetyl chloride (AcCl), we hypothesized that similar conditions 
could be used for the preparation of the allyl glycoside 13. In fact, 
treatment of L-sorbose with allyl alcohol and AcCl gave 13 in 64% 
yield.  However, at this stage we could not establish the 
stereochemical configuration of 13.  However, 1H-NMR analysis 
suggested the formation of the pyranose ring (J3,4 = 9.5 Hz; J5,6 = 
10.4; J4,5 = 8.7; J5,6’ = 5.4) had occurred.  Fortunately, 
regioselective protection of hydroxyl groups at C-1 and C-3 using 
anisaldehyde dimethyl acetal in presence of camphorsulphonic 
acid gave 14 in good yield (scheme 2) which crystallized from a 
mixture of MeOH-AcOEt 3:1. X-Ray crystal structure[24] 
determination of the resultant crystals confirmed the formation of 
the allyl α-L-sorbopyranoside 14 as the main product (see SI). The 
regioselective protection of diol 14 was next attempted.  
Unfortunately, the attempted reaction of 14 with TIPSCl in pyridine 
was not successful. Similar results were obtained when 14 was 
treated with MOMCl in pyridine. Fortunately, regioselective 
protection of 14 was achieved using MOMCl and DIPEA in 
dichloromethane, giving alcohol 15 in moderate yield (55%), 
together with small amounts of 16 (14%) and a mixture of 
regioisomers 15 and 17 (16%), after chromatography. We next 
attempt the protection of the secondary alcohol of 15 as the TBS 
ether. However, the introduction of the TBS group failed under 
several conditions (TBSOTf-TEA-THF, TBSOTf-NaH-THF, 
TBSOTf-DBU, TBSCl-NaH-DMF). Fortunately, treatment of 15 
with benzoyl chloride in pyridine gave 18 in excellent yield (93%). 
The analysis of NMR data for 19 confirmed that the hydroxyl 
group at C-4 was protected as the MOM ether while the hydroxyl 
group at C-5 was protected as the benzoate ester. In addition, the 
mixture of 15 and 17 obtained during regioselective MOM 
protection of 14 was reacted with BzCl in pyridine giving both 18 
and 21 that can be easily separated using chromatography. 
Treatment of the 3,6-O-p-methoxybenzylidene acetal 18 with 
NaCNBH3 and TMSCl[25] gave the corresponding 4-O-PMB ether 
19 in 59% yield.  
Next, the protection of the secondary hydroxyl group of 19 was 
attempted.  Unfortunately, protection of 19 as a TIPS ether was 
unsuccessful after several attempts (using TIPSCl or TIPSOTf, 
DMAP, DMF, 130 oC or TIPSOTf, NaH, THF, RT), with 19 being 
recovered unreacted. Surprisingly, even benzylation of 19 failed 
under several conditions (NaH and BnBr or Dudley´s reagent[26]).  
Instead, removal of the allyl group, followed by installation of the 
protecting group at C-3 were studied.  However, attempted 
removal of the allyl protecting group using PdCl2 at several 
different conditions gave the desired product in low yields (28-
41%). Fortunately, treatment of 19 with OsO4/NaIO4[23b] followed 
by the simultaneous protection of both the C-3 and C-6 OH groups 
as TBS ethers gave 20 in good yield (58% over two steps). With 
20 in hand, chain branching at C-2 using the Wittig reaction was 
investigated.  Treatment of 20 with Ph3PCH3Br and tBuOK gave 
the desired alkene 22 in 61% yield. Regioselective removal of the 
TBS group at the primary position of 22 using 10 % TsOH in 
MeOH gave a primary alcohol, which was oxidized using Ley-
Griffith conditions and gave aldehyde 23 in good yield. Again, 
compound 23 was reacted with Ph3PCH3Br and tBuOK to give 
diene 24 (Scheme 4). However, the reaction of 24 with the Grubbs 
2nd generation catalyst in toluene only gave a complex mixture at 
different temperatures (from 80 oC to reflux). Fortunately, RCM of 
24 in dichloromethane under microwave irradiation gave the 
orthogonally protected cyclopentene 25 in good yield (71%). 
Removal of PMB group in 25 was successful using DDQ-H2O 
leading to 26 (66%). Treatment of 26 with MnO2 gave the α,β-
unsaturated aldehyde 27 in 74% yield. Aldehyde 27 was then 
reacted with isopropenylmagnesium bromide to give secondary 
alcohol 28 (72%) that was finally oxidized with MnO2 giving the 
orthogonally protected advanced intermediate 7 in 93% yield 
(Scheme 3).  
Importantly, advanced intermediate 7 has potential to be used for 
the preparation of analogues of MDR modulators such as 
jatrophanes and can be also used for the preparation of 
biologically active cyclopentitols. In addition, intermediate 7 was 
screened against a panel of human cancer cell lines derived from 
colon (HT29, Ls174t, SW620), lung (A549) and cervical cancer 
(HeLa). We took advantage that 7 has a silyl ether, a feature that 
could increase cellular uptake and enhance anti-proliferative 
effects. In addition, It has also been demonstrated that no 
“element-specific” toxicity is associated with organosilicon 
compounds.[27] Padron and co-workers have demonstrated that 
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the presence of TBS ether enhance the anti-proliferative effects 
of tetrahydropyrans derivatives in HL60 (human promyelocytic 
leukemia) and MCF7 (human breast cancer) cell lines.[28] 
Furthermore, trialkylsilyl campothecine derivatives such as 
cositecan[29],[30] and DB-67[31] are promising compounds for 
cancer treatment and are currently in phase III and II clinical trials 
respectively.  
  
Scheme 2. a) Synthesis of open-chain intermediate 20; b) resolution of 15-17 
mixture; c) crystal structure of 14. 
Compound 7 showed good toxicity in the XTT assay with IC50 
range of 6.1-35.1 µM.  Compound 7 is generally less potent than 
widely used chemotherapeutics cisplatin or oxaliplatin while in 
HT29 colon cancer cell line, displayed an activity similar to 
cisplatin. Previous studies have demonstrated the ability of 
jathropane diterpenes to reduce the activity of ABC proteins linked 
with multi-drug resistance (MDR).[32] Compound 7 can be 
considered as an analogue of ring A of jatrophane (figure 1). In 
light of that, we decided to test 7 against ABCC2 (MRP2), ABCC3 
(MRP3) and ABCB1 (MDR1 or P-gp). At the concentration of 20 
µM, compound 7 show weakly inhibit ABCC2 (10.5 ± 0.25%), 
ABCC3 (6.1± 0.35%) and ABCB1 (7.1± 0.65%) indicating that 
truncated[33] jatrophane analogues might have potential to be 
developed into MDR modulators. 
 
  
Scheme 3. Synthesis of polyhydroxylated cyclopentene 7. 
In conclusions, we have developed a synthetic approach for the 
converstion of L-sorbose to allyl α-L-sorbopyranoside (13). This 
intermediate was turned into an orthogonally protected L-
sorbopyranose derivative (18).  The cleavage of the allyl glycoside 
in 19 is compatible with different protecting group (acidic, basic 
and single electron oxidation sensitive). Subsequently, we also 
prepared the orthogonal acyclic L-sorbose derivative (20): this 
intermediate can be used for the preparation of more complex 
chiral products.   We demonstrated its use in preparation of the 
orthogonally protected polyhydroxylated cyclopentene 7 which 
could have potential as an intermediate for the preparation of 
jatrophane analogues or for the preparation of cyclopentitols 
which are of particular significance because of their presence in a 
variety of medicinally relevant natural products. Compound, 7 was 
tested in a panel of human cancer cell lines (HT29, Ls174t, 
SW620, HeLa, A549) and displayed good cytotoxic activity. In 
addition, 7 weakly inhibit ABCB1 ABCC2 and ABCC3 
demonstrating that it could be used as a starting point for the 
development of truncated jatrophane analogues as multi drug 
resistance (MDR) modulators.  
 
Figure 2. Antiproliferative activity of 7: IC50 was determinated by XTT assay. a: 
see ref [34] 
Experimental Section 
General methods and materials. All NMR spectra were recorded using 
a 500 MHz spectrometer  at 30 oC.  Chemical shifts are reported relative 
to internal Me4Si in CDCl3 (δ 0.0 ppm) for 1H and CDCl3 (δ 77.16) for 13C 
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at 30 ºC, unless otherwise stated. The 13C signals were assigned with the 
aid of HSQC. The 1H-NMR signals were assigned with the aid of COSY. 
Coupling constants are reported in Hertz. High resolution mass spectra 
were measured using an LC Time-of-flight mass spectrometer and were 
measured in positive and/or negative mode as indicated. TLC were 
performed on aluminium sheets precoated with Silica Gel 60 (HF254, E. 
Merck) and spots visualized charring with vanillin solutions. Flash column 
chromatography was carried out using silica gel 60 (0.040-0.630 mm, E. 
Merck). Dichloromethane, tetrahydrofuran, MeOH, and toluene were used 
as obtained from a PureSolvTM solvent purification system. Petroleum 
ether is the fraction with bp 40-60 ºC.   
Allyl 1,3-O-(4-methoxybenzylidine)-α-L-sorbopyranoside (14). To a 
stirred solution of 13 (2.364 g; 10.7 mmol) in DMF (23 mL), 
camphorsulphonic acid (248 mg; 1.07 mmol) and anisaldehyde dimethyl 
acetal (1.82 mL; 10.7 mmol) were added. The solution was stirred at room 
temperature for 5 h. The mixture was diluted with Et2O (30 mL) and 
washed several times with water. The solvent was evaporated and flash  
chromatography (EtOAc-petroleum ether 3:1) gave 14 as a white solid 
(2.91 g; 80%); m.p. = 104 oC-109 oC; [α]
D 
- 41 (c 0.69, CHCl3); 1H NMR 
(CDCl3, 500 MHz): δ 7.48 – 7.36 (d, J = 8.8 Hz, 2H, ArCH), 6.91 – 6.82 (d, 
J = 8.7 Hz, 2H, ArCH 5.99 (ddt, Jtrans = 16.9, Jcis = 10.5, 5.3 Hz, 1H, 
OCH2CH=CH2), 5.51 (s, 1H, OCHO), 5.37 (dd, 1H, J = 17.3, Jgem = 1.7 Hz, 
OCH2CH=CH2), 5.18 (dd, 1H, Jcis = 10.6, OCH2CH=CH2), 4.26 (dd, 1H, J 
= 12.1, 2.0 Hz, CH2), 4.18 – 4.11 (m, 1H, OCH2CH=CH2), 4.11 – 3.98 (m, 
2H, OCH2CH=CH2, CH), 3.79 (s, 3H, J = 1.4 Hz, OCH3), 3.75 – 3.62 (m, 
2H, CH2, CH), 3.58 – 3.49 (m, 2H, CH2), 3.44 (dd, 1H, J = 9.8, 2.7 Hz, CH); 
13C NMR (CDCl3, 125 MHz): 160.4 (ArC), 134.4 (OCH2CH=CH2), 129.7 
(ArC), 128.0, (ArCH), 116.7 (OCH2CH=CH2), 113.8 (ArCH), 102.7 
(OCHO), 92.8 (C-2), 82.0 (CH), 71.2 (CH), 70.7 (CH), 68.2 (CH2), 63.3 
(CH2), 62.0 (CH2), 55.5 (OCH3); HRMS-ESI: calcd for C17H22O7Na: 
361.1263; Found: 361.1266 (M+Na+). 
Allyl 5-O-benzoyl-1,3-O-(4-methoxybenzylidine)-4-O-
(methoxymethoxy)-α-L-sorbopyranoside (18). To a stirred solution of 
15 (430 mg; 1.12 mmol) in pyridine (10 mL) at 0 oC, BzCl (195 µL; 1.68 
mmol) was added. The mixture was stirred at room temperature for 18 h. 
TLC (petroleum ether-EtOAc, 2:1) showed a new spot with higher Rf and 
the absence of 15. The solution was diluted with dichloromethane (20 mL), 
and washed with 1% HCl (20 mL), dried over Na2SO4, filtered and the 
solvent was removed.  Flash chromatography) (cyclohexane-EtOAc, 5:1) 
gave 18 as a yellow oil (508 mg; 93 %); [α]
D
: -17.16 (c 0.85, CHCl3); 1H 
NMR (CDCl3, 500 MHz): 8.09 (m, 2H, ArCH), 7.60–7.55 (m, 1H, ArCH), 
7.47–7.43 (m, 4H, ArCH), 6.89 (d, 2H, J -= 8.8 Hz, ArCH), 6.03 (ddt, 1H, 
Jtrans = 17.3, Jcis =10.6, 5.4 Hz, OCH2CH=CH2), 5.59 (s, 1H, OCHO), 5.40 
(dd, 1H, Jtrans = 17.2, J = 1.7 Hz, OCH2CH=CH2), 5.27–5.16 (m, 2H, 
OCH2CH=CH2, H-5), 4.84 (d, 1H, J = 6.8 Hz, OCH2O), 4.67 (d, 1H, 
OCH2O), 4.47 (dd, 1H, J3,4 = J4,5 = 9.4 Hz, H-4), 4.32 (d, 1H, J1,1’ = 12.1 
Hz, H-1), 4.21 (ddt, 1H, J = 12.7, 5.1, 1.6 Hz, OCH2CH=CH2), 4.08 (ddt, 
1H, J = 12.7, 5.1, 1.6 Hz, OCH2CH=CH2), 4.01 (dd, 1H, J6,6’ = 10.6, J6,5 =  
6.4 Hz, H-6), 3.81 (s, 3H, ArOCH3), 3.74 (d, 1H, H-3), 3.68 – 3.61 (m, 2H, 
H-1’,6’), 3.18 (s, 3H, OCH2OCH3); 13C NMR (CDCl3, 125 MHz): δ 165.8 
(CO), 160.3 (ArC), 134.4(OCH2CH=CH2), 133.5 (ArCH), 129.9 (ArC), 
129.9 (ArCH), 129.6 (ArC), 128.6 (ArCH), 127.8 (ArCH), 116.8 
(OCH2CH=CH2), 113.7 (ArCH), 102.4 (OCHO), 97.3 (OCH2O), 93.0 (C-2), 
82.1 (C-3), 73.0 (C-4), 71.7 (C-5), 68.1 (C-1), 62.3 (OCH2CH=CH2), 60.9 
(C-6), 55.8 (OCH2OCH3), 55.4 (ArOCH3); HRMS-ESI: calcd for 
C26H30O9Na: 509.1788; Found: 509.1788 (M+Na+). 
5-O-benzoyl-3,6-di-O-(Tert-butyldimethylsilyl)-1-O-(4-
methoxybenzyl)-4-O-(methoxymethoxy)-L-sorbose (20). To a stirred 
solution of 19 (657 mg; 1.34 mmol) in dioxane (6.5 mL) and H2O (0.7 mL), 
NMO (473 mg; 4.039 mmol), OsO4 (1.419 mL; ~ 0.134 mmol, 2.5% in t-
BuOH), NaIO4 (1.146 g; 5.36 mmol) and H2O (2.6 mL) were added. The 
resulting solution was stirred at 60 oC for 24 h. TLC (petroleum ether-
EtOAc 1:1) showed a new spot with lower Rf and the absence of 19. The 
mixture was diluted with dichloromethane and washed with H2O. The 
organic layers were washed with aq satd Na2S2O3.  The organic phase 
was dried and the solvent was removed. The crude mixture was dissolved 
in DMF (6.5 mL), DIPEA (1.87 mL; 10.72 mmol) and TBSOTf (1.229 mL; 
5.36 mmol) were added and the resulting solution was stirred at 80 oC for 
18h. TLC (petroleum ether-EtOAc 1:1) showed a new spot with higher Rf 
and the absence of starting material. The solution was diluted with 
dichloromethane and washed with H2O. The organic phase was dried and 
the solvent was removed.  Flash chromatography (cyclohexane-EtOAc, 
30:1 to 10:1 gradient elution gave 20 as a yellow oil (525 mg; 58 % over 
two steps); [α]D
 
, - 19.6° (c 0.41, CHCl
3
); 1H NMR (CDCl3, 500 MHz): δ 
8.03–7.97 (m, 2H, ArCH), 7.55–7.50 (m, 1H, ArCH), 7.41 (t, 2H, J = 7.8 
Hz, ArCH), 7.09 (d, 2H, J = 8.6 Hz, ArCH), 6.79 (d, 2H, J = 8.6 Hz, ArCH), 
5.39 (td, 1H, J = 5.8, 4.3 Hz, H-5), 4.75 (d, 2H, J = 1.6 Hz, CH2), 4.50 (d, 
1H, J=5.1 Hz, H-3), 4.34 – 4.24 (m, 2H, CH2), 4.22 – 4.13 (m, 3H, H-4 and 
CH2), 3.85 (dd, 2H, J = 5.9, 1.4 Hz, H-6), 3.78 (s, 3H, ArOCH3), 3.39 (s, 
3H, OCH2OCH3), 0.90 (s, 9H, C(CH3)3), 0.86 (s, 9H, C(CH3)3), 0.08 (s, 3H, 
SiCH3), 0.03 (m, 9H, 3SiCH3); 13C NMR (CDCl3, 125 MHz): δ 206.3 (C=O), 
165.8 (C=O), 159.4 (ArC), 133.2 (ArCH), 130.0 (ArCH), 129.9 (ArC), 129.6 
(ArCH), 129.5 (ArC), 128.5 (ArCH), 113.8 (ArCH), 98.2 (CH2), 77.5 (C-4), 
76.3 (C-3), 73.1 (CH2), 72.9 (CH2), 60.5 (C-5), 56.4 (CH2), 55.4 (ArOCH3), 
25.9 (C(CH3)3), 18.2 (C(CH3)3), -4.8 (SiCH3), -4.8 (SiCH3), -5.2 (SiCH3), -
5.4 (SiCH3); HRMS-ESI: calcd for C35H56O9Si2Na: 699.3361; Found: 
699.3354 (M+Na+). 
(1S,4R,5R)-4-(Tert-butyldimethylsilyl)oxy)-3-methacryloyl-5-
(methoxymethoxy)cyclopent-2-en-1-yl benzoate (7). To a stirred 
solution of 28 (20.0 mg; 0.045 mmol) in dichloromethane (1.0 mL), MnO2 
(39 mg; 0.45 mmol) was added. The resulting solution was stirred at room 
temperature for 48 h. The mixture was filtered through celite with 
dichloromethane (50 mL) and the solvent was removed. The crude was re-
dissolved in dichloromethane (1.0 mL), MnO2 (20 mg; 0.23 mmol) was 
added and the resulting mixture was stirred at room temperature for 
additional 6 h. The mixture was filtered through celite with dichloromethane 
(50 mL) and the solvent was removed.  Flash chromatography (EtOAc-
cyclohexane  1:10) gave  7 as a yellow oil (18.7 mg; 93%); 1H NMR (CDCl3, 
500 MHz): δ 8.12 – 8.06 (m, 2H, ArCH), 7.61 – 7.56 (m, 1H, ArCH), 7.46 
(t, 2H, J = 7.8 Hz, ArCH), 6.16 (d, 1H, J1,2 = 1.9 Hz, H-2), 6.00 (s, 1H, 
C(Me)=CH2), 5.90 (s, 1H, C(Me)=CH2), 5.71 (dd, 1H, J1,5 = 4.4 Hz, H-1), 
5.02 (d, 1H, J4,5 = 4.0 Hz, H-4), 4.77 (q, 2H, J = 6.8 Hz, OCH2O), 4.29 
(appt, 1H, J1,4 = J1,5 =4.2 Hz, H-5), 3.33 (s, 3H, OCH3), 1.93 (s, 3H, 
C(Me)=CH2), 0.85 (s, 9H, C(CH3)3), 0.15 (s, 3H, SiCH3 ), 0.07 (s, 3H, 
SiCH3); 13C NMR (CDCl3, 125 MHz): δ 194.5 (C=O), 166.1 (C=O), 146.4 
(C), 144.5 (C), 133.4 (ArCH), 133.2 (C-2), 130.0 (C), 129.9 (ArCH), 128.8 
(C(Me)=CH2), 128.6 (ArCH), 97.2 (OCH2O), 90.6 (C-5), 79.9 (C-1), 78.7 
(C-4), 56.1 (OCH3), 25.8 (C(CH3)3), 18.1 (C(Me)=CH2), 17.4 (C(CH3)3), -
4.6 (SiCH3), -5.0 (SiCH3);  HRMS-ESI: calcd for C24H34O6SiNa: 469.2022; 
Found: 469.2015. 
Cell Culture. A549 (non-small cell lung cancer, human), HT29 (colorectal 
adenocarcinoma, human), SW620 (colorectal, Dukes’ type C, human) and 
Ls174t (colorectal, Dukes’ type B, human), HeLa (cervix adenocarcinoma, 
human) cells were grown in 75 cm2 culture flasks (Corning® Flask) as 
adherent monolayer cultures in Dulbecco´s Modified Eagle Medium 
(DMEM) (GIBCO, ref. 41966-029). Culture mediums were supplemented 
with 10% heat-inactivated fetal bovine serum, and with 
Penicillin/Streptomycin (Gibco, 15140-122). Cultures were maintained at 
37 °C in a humidified atmosphere containing 5% CO2 and 95% air. 
Inhibition of Cell Viability Assay. Drug effects on exponentially growing 
tumour cells were determined using XTT assay as described previously.35 
A549, HT29, SW620, Ls174t, HeLa cells were seeded at a density of 3000 
cells/well in 96-well plates and incubated for 24h. Thereafter, cancer cells 
were exposed to drugs at different concentrations during 72h. At 72h, 50 
μL of XTT/ECR 1:50 solution was added and incubated for a further 4 h at 
37 oC. .Absorbance measured at 475 nm was converted to percentages. 
UV-vis absorbance was measured at 475 nM using a microplate reader. 
Experiments were performed in triplicated for each drug concentration and 
carried out independently at least three times. The interpolation analysis 
was done using dose-dependent inhibition pattern (log3d vs. normalized 
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response {Variable slope}) with Prism version 5.00 software (GraphPad 
Software, USA).  
Drug transporter inhibition assay. Cells are seeded in a 96-well culture 
plate typically at 20,000 cells/well and are used on days 2 or 3 post-
seeding. On the day of assay the test compound is prepared in assay 
buffer (HBSS-HEPES, pH 7.4), added to the cell plate, and pre-incubated 
at 37 oC for 15 min. Subsequently substrate is added to the plate followed 
by 20-min incubation at 37 oC. The plate is then washed with cold assay 
buffer followed by fluorescence reading for assays with fluorogenic 
substrates. Cell lines: MDR1-MDCKII (Transporter: P-gp, substrate: 
Calcein AM, positive control Verapamil IC50 = 29 µM); MRP2-HEK 
(Transporter: MRP2, substrate CDCF, positive control MK571 IC50 = 14 
µM); -HEK; MRP3-HEK (Transporter: MRP2, substrate CDCF, positive 
control MK571 IC50 = 12 µM).  
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